All In Biotech

NDA 216655 · Xiamen Lp Pharm CO

Opipza

Aripiprazole · Oral · Atypical Antipsychotic

Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 22, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

401

123 Phase 3, 18 recruiting

FAERS reports

42,264

35,961 serious, 3,404 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIARELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. OPIPZA is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 ) Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. ( 5.3 ) Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic...

What it is approved for

From the label in effect Jan 30, 2025.

OPIPZA is indicated for the: treatment of schizophrenia in patients ages 13 years and older adjunctive treatment of major depressive disorder (MDD) in adults treatment of irritability associated with autistic disorder in pediatric patients 6 years and older treatment of Tourette's disorder in pediatric patients 6 years and older OPIPZA is an atypical antipsychotic indicated for: treatment of schizophrenia in patients ages 13 years and older ( 1 ) adjunctive treatment of major depressive disorder (MDD) in adults ( 1 ) irritability associated with autistic disorder in pediatric patients 6 years and older ( 1 ) treatment of Tourette's disorder in pediatric patients 6 years and older ( 1 )

Mechanism: The mechanism of action of aripiprazole in the listed indications, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • OPIPZA · ARIPIPRAZOLE 10MG · FILM, ORAL · Prescription
  • OPIPZA · ARIPIPRAZOLE 2MG · FILM, ORAL · Prescription
  • OPIPZA · ARIPIPRAZOLE 5MG · FILM, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aripiprazole" as an intervention, any sponsor and status, largest first.

All 401 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,421
  • off label use2,952
  • drug interaction2,286
  • product use in unapproved indication2,270
  • weight increased2,162
  • anxiety1,796
  • condition aggravated1,712
  • suicide attempt1,582
  • fatigue1,545
  • suicidal ideation1,449
  • toxicity to various agents1,429
  • nausea1,385

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200468
2005111
2006161
2007217
2008192
2009256
2010342
2011354
2012534
2013428
2014584
20151,211
20161,456
20172,955
20183,363
20193,484
20203,049
20213,704
20223,702
20234,151
20244,228
20254,180
20263,534

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,035 on PubMed

Sponsor: Xiamen Lp Pharm CO

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.